Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Pfizer Launches Janus Kinase 3 (JAK3) Inhibitor PF-06651600
Pfizer launched its investigational oral Janus Kinase 3 (JAK3) inhibitor PF-06651600, which is used for the treatment of patients with alopecia areata. Alopecia areata is chronic autoimmune skin disease in which immune cells attack healthy hair...
Alnylam’s ONPATTRO to Treat Patients with Hereditary ATTR Amyloidosis in Adults
Our research focused on developing ion-pairing HPLC methods with UV detection for the precise determination of two widely used chelating agents: ethylenediaminetetraacetic acid (EDTA) in Abilify® oral solution and diethylenetriaminepentaacetic acid...
Encorafenib (BRAFTOVI™) to Treat Patients with BRAFV600E-Mutant Metastatic Colorectal Cancer (mCRC)
<p xss=removed>Encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab has been designed to treat patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).</p> <p xss=removed>BRAFV600E-mutant mCRC will be an important treatment option to the cancer patients in critical need.</p> <p xss=removed>The results were made from the safety lead-in of the ongoing randomised Phase 3 BEACON CRC trial showed that, at ...
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Treats Relapsed/Refractory FLT3-ITD AML
<p xss=removed>Daiichi Sankyo Company, Limited announced quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD Acute Myeloid Leukemia (AML).</p> <p xss=removed>Quizartinib is the first FLT3 inhibitor to enhance overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory AML with FLT3-ITD, an underlying driver of this subtype of AML.</p> ...
Portola Pharmaceuticals Introduces Antidote for the Reversal of Factor Xa Inhibitors
Portola Pharmaceuticals is the developer of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote designed for patients undergoing treatment with rivaroxaban and apixaban...
Amgen and Novartis Pharma Collaborate to Develop Novel Approach for Migraine Prevention
Aimovig™, developed through a collaboration between Amgen and Novartis Pharma AG, introduces a novel therapeutic approach for the prevention of migraines. It achieves this by blocking the calcitonin gene-related peptide receptor...
World's First Metal-based Probes for Detection of Dopamine Receptors - Developed by HKBU Researchers
A groundbreaking achievement has been made by a team of researchers from Hong Kong Baptist University, who have successfully developed the world's first metal-based probes for identifying dopamine receptors in living cells...
ChargePoint Technology launches VERIFI®- a Intelligent Monitoring Hub
<p xss=removed>ChargePoint Technology launches first-of-its-kind intelligent monitoring platform namely VERIFI which helps in tracking the most critical data of numerous valve installations. This will send alerts directly to H&S, maintenance and compliance teams to reduce unplanned maintenance downtime.</p> <p xss=removed>The VERIFI comprises an open/close handle which can be connected directly to ChargePoint valve for continuous recording of ...
First-of-its-kind Doptelet will soon be Available to Control Life-threatening Bleeding
Dova Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted approval for the prescription medicine Doptelet...
Roche Launches Hemlibra to Treat Haemophilia A without Factor VIII Inhibitors
<p>Roche launches Hemlibra for the treatment of people suffering from haemophilia A without factor VIII inhibitors.</p> <p>Hemlibra is a bispecific medicine which is injected under the patient’s skin in order to develop required proteins, activate the natural coagulation cascade and to restore the blood clotting process for people affecting with haemophilia A.</p> <p>This is a first-ever medicine to exhibit superior efficacy compared to fac...
